Results 191 to 200 of about 721,295 (295)
BMP9 Modulates IL-33 Signaling to Mitigate EndMT in Pulmonary Arterial Hypertension. [PDF]
Becher C +12 more
europepmc +1 more source
This study presents a two‐stage portal flow modulation strategy for graft procurement in living donor liver transplantation with the aim of expanding left lateral lobe grafts, thereby circumventing technical and anatomical limitations of conventional approaches.
Yuqi Gong +6 more
wiley +1 more source
A Case of Atrial Septal Defect Unveiled by the Treatment for Pulmonary Arterial Hypertension. [PDF]
Fujii T +12 more
europepmc +1 more source
Establishment of a mouse model of TMAO‐induced cardiac injury and application of MICT intervention
This study aims to explore the establishment of an animal model of cardiac injury induced by trimethylamine‐N‐oxide (TMAO), a metabolite secreted by gut microorganisms, and to investigate its application in moderate‐intensity continuous training (MICT) intervention.
Zhongping Xie +4 more
wiley +1 more source
Pulmonary Arterial Hypertension: Recognition and Management in Primary and Acute Care Settings. [PDF]
Ahern BJ, Fulford ST, Long D, Miller CL.
europepmc +1 more source
Clinical–Radiological Spectrum of Cerebral Amyloid Angiopathy‐Related Inflammation
Objective To identify clinical and radiological features of cerebral amyloid angiopathy‐related inflammation (CAA‐ri), and compare these features with those of sporadic CAA, to improve the understanding, diagnosis, and clinical care of CAA‐ri. Methods We retrospectively reviewed routine clinical data from 37 patients with CAA‐ri and 158 patients with ...
Larysa Panteleienko +9 more
wiley +1 more source
Pulmonary arterial hypertension associated with toxic rapeseed oil: a continuous disease? [PDF]
Grynblat J, Khouri C, Montani D.
europepmc +1 more source
Back Again to the Future: A New Era for Cerebroprotection
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley +1 more source

